



Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-May-2018
Document Type: USP Monographs
DocId: GUID-9AB77E86-12B3-4A8F-8D0B-935CA3509AEC_3_en-US
DOI: https://doi.org/10.31003/USPNF_M41253_03_01
DOI Ref: psu29

© 2025 USPC
Do not distribute

lobenguane I 123 Injection



[[3-(Iodo- 123 I)-phenyl]methyl]guanidine sulfate (2:1).

(*m*-Iodo- 123 I)-benzyl)guanidine sulfate (2:1)

CAS RN®: 139755-80-9.

» lobenguane I 123 Injection is a sterile solution containing lobenguane sulfate in which a portion of the molecules contain radioactive iodine (123 I) in the molecular structure. lobenguane I 123 Injection contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of I 123 as lobenguane expressed in megabecquerels (or in millicuries) per mL at the time indicated in the labeling. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of lobenguane. It may contain preservatives or stabilizers.

Packaging and storage—Preserve in single-dose or in multiple-dose containers that are adequately shielded. Store in a freezer.

Labeling—Label it to include the following: the time and date of calibration; the amount of 123 I as lobenguane expressed as total megabecquerels (or millicuries) per mL at the time of calibration; the name and quantity of any added preservative or stabilizer; the expiration time; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 123 I is 13.2 hours.

RADIONUCLIDIC IDENTIFICATION (see [Radioactivity \(821\)](#))—Its gamma-ray spectrum is identical to that of a specimen of 123 I of known purity that exhibits a major photopeak having an energy of 159 KeV.

BACTERIAL ENDOTOXINS TEST (85)—It contains not more than 175/V USP Endotoxin Unit per mL of the Injection, when compared with the [USP Endotoxin RS](#), in which V is the maximum recommended total dose, in mL, at the expiration time.

pH (791): between 6.0 and 7.5.

Radionuclidic purity (see [Radioactivity\(821\)](#))—Using a suitable counting assembly, determine the radionuclidic purity of the Injection: not less than 97% of the total radioactivity is present as 123 I.

Radiochemical purity—

METHOD 1(High-pressure liquid chromatographic method)—

Mobile phase, Standard preparation, and Chromatographic system—Proceed as directed in the Assay for lobenguane sulfate, except that the liquid chromatograph is also equipped with a collimated radiation detector (see [Radioactivity \(821\)](#)).

Test preparation—Use lobenguane I 123 Injection.

Procedure—Inject a volume (about 20 μ L) of Injection, equivalent to 1.6 to 2.7 MBq (44 to 64 μ Ci) of the Injection into the chromatograph, record the chromatogram, and measure the areas for the major peaks. The radioactivity of the lobenguane 123 I peak is not less than 90% of the total radioactivity measured, and its retention time is within 10% of that in the chromatogram of the *Standard preparation* obtained in the Assay for lobenguane sulfate.

METHOD 2(Thin-layer chromatographic method)—Apply 0.2 to 0.4 μ L of the Injection 10 mm from one end of a 20- \times 200-mm silica gel glass plate (see [Chromatography \(621\)](#)), and allow to dry. Develop the chromatogram by ascending chromatography until the solvent front has moved 100 mm from the origin (about 20 minutes), using a solvent system consisting of a mixture of alcohol, ethyl acetate, and ammonium hydroxide (20:20:1). Air-dry the chromatogram, and determine the radioactivity distribution by scanning the chromatogram with a collimated radiation detector: not less than 90% of the total radioactivity is found as 123 I at the origin.

Other requirements—It meets the requirements under [Injections and Implanted Drug Products \(1\)](#), except that the Injection may be distributed or dispensed prior to the completion of the test for [Sterility Tests \(71\)](#), the latter test being started on the day of final manufacture, and except

that it is not subject to the recommendation on *Container Content*.

Assay for lobenguane sulfate—

Mobile phase—Prepare a filtered and degassed mixture of water and acetonitrile (900:100). Add 3.04 g of triethylamine per liter, and adjust with phosphoric acid to a pH of 4. Make adjustments if necessary (see [System Suitability](#) under [Chromatography \(621\)](#)).

Standard preparation—Using an accurately weighed quantity of lobenguane sulfate, prepare a solution in water having a known concentration of about 1 mg per mL.

Assay preparation—Use the Injection, which has not yet been brought to full volume with bacteriostatic saline.

Chromatographic system (see [Chromatography \(621\)](#))—The liquid chromatograph is equipped with a 229-nm detector and a 4.6-mm × 25-cm column that contains 10-μm packing L1. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed under *Procedure*: the column efficiency is not less than 1000 theoretical plates, the tailing factor is not more than 1.2, and the relative standard deviation for replicate injections is not more than 1.5%.

Procedure—Separately inject equal volumes (about 20 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of lobenguane sulfate in each mL of the Injection taken by the formula:

$$C(r_u/r_s)$$

in which *C* is the concentration, in mg per mL, of lobenguane sulfate in the *Standard preparation*; and r_u and r_s are the lobenguane peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Assay for radioactivity—Using a counting assembly, determine the radioactivity, in MBq (or μCi), per mL, of the Injection by use of a calibrated system as directed under [Radioactivity \(821\)](#).

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
IOBENGUANE I 123 INJECTION	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: [GUID-9AB77E86-12B3-4A8F-8D0B-935CA3509AEC_3_en-US](#)

Previous DocID: [GUID-9AB77E86-12B3-4A8F-8D0B-935CA3509AEC_1_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M41253_03_01

DOI ref: [psu29](#)